Clinical Trial Update: GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Liver Cancer [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for a GP96 heat shock protein-peptide complex vaccine being studied in liver cancer across Phase 2 and Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Cancer

Drugs mentioned

• gp96 heat shock protein peptide complex vaccine (gp96 heat shock protein peptide complex)

Snippet

Sponsor: Cure&Sure Biotech Co., LTD | Conditions: Liver Cancer | Phase 2, Phase 3 | Status: UNKNOWN